The Scleroderma Foundation Teams Up with Traitwise PDF Print E-mail
Tuesday, 16 February 2010 14:40
The Scleroderma Foundation has teamed up with Austin, TX company, Traitwise Incorporated, to launch a unique survey to poll thousands of scleroderma patients and their caregivers. Data from the survey will be shared with researchers nationally and internationally in an effort to improve understanding and treatment of scleroderma.

By gathering answers about everything from symptoms to family history of disease to quality of life - and then comparing every answer to every other answer - the survey mechanism promises to tease out previously unsuspected patterns that can lead to new diagnostics, treatments, and even a cure for this chronic autoimmune disease that afflicts approximately one in every thousand people.

"As common as it is and despite the heroic efforts of clinicians and researchers, scleroderma still isn't well understood," said Scleroderma Foundation CEO Robert Riggs. "The Traitwise survey gives us a chance to assemble and analyze more pieces of the puzzle and really move research forward."

The unique Traitwise approach to data security allows users to volunteer information without fear that the information will be shared or used to identify them. Once it's made anonymous, data will be made available to researchers through the Scleroderma Foundation. "We understand that the information we seek is sensitive and personal," said Executive Vice President Michael Simpson of Traitwise. "So we answer every user's privacy expectation with an iron-clad commitment to protect their personal information."

Source: MMD Newswire
 
More articles :

» What's Your Scleroderma Action Plan?

Living with any serious disease or condition like Scleroderma, is without a doubt, difficult. It is not hard to understand either, that we often can lose sight of what is important, including our way. We may also fall into to a false sense of...

» Identification of New Autoantibody Specificities Directed at Proteins Involved in the Transforming Growth Factor Beta Pathway in Patients with Systemic Sclerosis

Guillaume BussoneHanadi DibMathieu TambyCedric BroussardChristian FedericiGenevieve WoimantLuc CamoinLoic GuillevinLuc MouthonArthritis Research &Therapy 2011, 13:R74IntroductionAntinuclear antibodies (ANA), usually detected by indirect...

» More Research Needed to Understand Scleroderma

With an estimated 14 million cases worldwide, you would think more would be known about , a chronic, debilitating disease that can lead to the hardening and tightening of skin and connective tissue. But it seems that we don’t know enough: “We...

» The Secrets of An Ancient Chinese Remedy, Revealed

For roughly two thousand years, Chinese herbalists have treated malaria using a root extract, commonly known as Chang Shan, from a type of that grows in Tibet and Nepal. Recent studies suggest that , a compound derived from the extract’s bioactive...

» Placebo-controlled Study of Methotrexate in Juvenile Localised Scleroderma

According to the results of this placebo-controlled study, is an effective treatment for juvenile localised scleroderma (JLS). The authors note that JLS is a chronic progressive fibrotic process of the skin causing permanent disability and...

» New Hope for Patients

Pulmonary Fibrosis (PF) and (PAH) are incurable rare lung diseases and are the leading cause of mortality in patients with Systemic Sclerosis (SSc). However patients might have a reason to breathe easier since researchers from the University of...